| Asthma
Breyna vs Qvar RediHaler
Side-by-side clinical, coverage, and cost comparison for asthma.Deep comparison between: Breyna vs Qvar Redihaler with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsQvar Redihaler has a higher rate of injection site reactions vs Breyna based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Qvar Redihaler but not Breyna, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Breyna
Qvar Redihaler
At A Glance
Oral inhalation
Twice daily
ICS/LABA combination
Oral inhalation
Twice daily
Inhaled corticosteroid
Indications
- Asthma
- Chronic Obstructive Airway Disease
- Bronchitis, Chronic
- Pulmonary Emphysema
- Asthma
Dosing
Asthma (12 years and older) 2 inhalations of 80 mcg/4.5 mcg or 160 mcg/4.5 mcg twice daily by oral inhalation; starting dose based on asthma severity.
Asthma (6 to <12 years) 2 inhalations of 80 mcg/4.5 mcg twice daily by oral inhalation.
Chronic Obstructive Airway Disease, Bronchitis, Chronic, Pulmonary Emphysema 2 inhalations of 160 mcg/4.5 mcg twice daily by oral inhalation.
Asthma (adults and adolescents, >=12 years) 40 to 320 mcg twice daily by oral inhalation, approximately 12 hours apart; starting dose 40 to 80 mcg twice daily for those not on an inhaled corticosteroid; maximum 320 mcg twice daily.
Asthma (pediatric, 4 to 11 years) 40 mcg twice daily by oral inhalation, approximately 12 hours apart; may increase to 80 mcg twice daily after 2 weeks if needed; maximum 80 mcg twice daily.
Contraindications
- Primary treatment of status asthmaticus or other acute episodes of asthma or COPD where intensive measures are required
- Hypersensitivity to any ingredient in BREYNA
- Primary treatment of status asthmaticus or other acute asthma episodes requiring intensive measures
- Known hypersensitivity to beclomethasone dipropionate or any ingredient in QVAR REDIHALER
Adverse Reactions
Most common (>=3%) Nasopharyngitis, headache, upper respiratory tract infection, pharyngolaryngeal pain, sinusitis, oral candidiasis, bronchitis, influenza
Serious Serious asthma-related events (hospitalizations, intubations, death), cardiovascular and CNS effects, Candida albicans infection, pneumonia or lower respiratory tract infections in COPD, immunosuppression, hypercorticism, adrenal suppression
Postmarketing Angina pectoris, tachycardia, atrial fibrillation, cataract, glaucoma, oropharyngeal candidiasis, anaphylactic reaction, hyperglycemia, hypokalemia, tremor, dysphonia, hypotension, hypertension
Most common (>=3%) oral candidiasis, upper respiratory tract infection, nasopharyngitis, oropharyngeal pain, viral upper respiratory tract infection, sinusitis, pharyngitis, headache, pyrexia
Serious oropharyngeal candidiasis, immunosuppression and risk of infections, hypercorticism and adrenal suppression, reduction in bone mineral density, growth effects, glaucoma and cataracts
Postmarketing localized Candida infections, aggression, depression, sleep disorders, psychomotor hyperactivity, suicidal ideation (primarily in children), blurred vision, central serous chorioretinopathy
Pharmacology
Budesonide is an inhaled corticosteroid that suppresses inflammation by inhibiting multiple cell types and mediators involved in allergic and non-allergic inflammation; formoterol is a long-acting selective beta2-adrenergic agonist that relaxes bronchial smooth muscle by stimulating adenyl cyclase and increasing intracellular cyclic AMP.
Inhaled corticosteroid prodrug; beclomethasone dipropionate is rapidly hydrolyzed to the active monoester 17-monopropionate (17-BMP), which inhibits inflammatory cells (mast cells, eosinophils, basophils, lymphocytes, macrophages, neutrophils) and release of inflammatory mediators (histamine, eicosanoids, leukotrienes, cytokines) to reduce airway inflammation in asthma.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Breyna
- Covered on 5 commercial plans
- PA (1/12) · Step Therapy (0/12) · Qty limit (11/12)
Qvar Redihaler
- Covered on 5 commercial plans
- PA (3/12) · Step Therapy (0/12) · Qty limit (9/12)
UnitedHealthcare
Breyna
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (2/8)
Qvar Redihaler
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (8/8)
Humana
Breyna
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (0/3) · Qty limit (1/3)
Qvar Redihaler
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (3/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Breyna.
No savings programs available for Qvar Redihaler.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
BreynaView full Breyna profile
Qvar RedihalerView full Qvar Redihaler profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.